{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:32:59Z","timestamp":1792092779832,"version":"4.4.0"},"reference-count":39,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,11,15]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Checkpoint inhibitors best perform in neoadjuvant settings for a number of solid malignancies including cutaneous melanoma as compared with adjuvant schemes. A key difference between both treatment settings is the availability of tumor antigens to continuously prime antitumor T lymphocytes. Mounting evidence indicates that priming is a function chiefly performed by a subset of dendritic cells that cross-present tumor antigens rather than by malignant cells themselves. Acting in favor of these mechanisms to foster tumor-antigen priming is proposed to enhance the efficacy of adjuvant schemes.<\/jats:p>","DOI":"10.1136\/jitc-2025-013766","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:15:39Z","timestamp":1765278939000},"page":"e013766","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Reframing adjuvant immunotherapy in melanoma: all of it starts with priming"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A","family":"Ascierto","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi di Napoli Federico II, Napoli, Campania, Italy"},{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Center for Applied Medical Research and Clinica Universidad de Navarra, University of Navarra, Pamplona, Navarre, Spain"},{"name":"Nuffield Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2025120902351235000_13.12.e013766.1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025120902351235000_13.12.e013766.2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9611","article-title":"KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma","volume":"41","author":"Long","year":"2023","journal-title":"JCO"},{"key":"2025120902351235000_13.12.e013766.3","doi-asserted-by":"crossref","unstructured":"Long GV , Ascierto PA , Guo J , et al . Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III\u2013IV melanoma: Primary results from RELATIVITY-098. JCO 2025;43. doi:10.1200\/JCO.2025.43.17_suppl.LBA9500","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9500"},{"key":"2025120902351235000_13.12.e013766.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102962","article-title":"Adjuvant immunotherapy for melanoma patients: progress and opportunities","volume":"9","author":"Sussman","year":"2024","journal-title":"ESMO Open"},{"key":"2025120902351235000_13.12.e013766.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"2025120902351235000_13.12.e013766.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006628","article-title":"Vaccinating against cancer: getting to prime time","volume":"11","author":"Chang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025120902351235000_13.12.e013766.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7"},{"key":"2025120902351235000_13.12.e013766.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2025120902351235000_13.12.e013766.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"2025120902351235000_13.12.e013766.10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025120902351235000_13.12.e013766.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630"},{"key":"2025120902351235000_13.12.e013766.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36"},{"key":"2025120902351235000_13.12.e013766.13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703"},{"key":"2025120902351235000_13.12.e013766.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.11.014"},{"key":"2025120902351235000_13.12.e013766.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107"},{"key":"2025120902351235000_13.12.e013766.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.09.024"},{"key":"2025120902351235000_13.12.e013766.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.10.009"},{"key":"2025120902351235000_13.12.e013766.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"2025120902351235000_13.12.e013766.19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2025120902351235000_13.12.e013766.20","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9306","article-title":"Functional classification of memory CD8(+) T cells by CX3CR1 expression","volume":"6","author":"B\u00f6ttcher","year":"2015","journal-title":"Nat Commun"},{"key":"2025120902351235000_13.12.e013766.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1836-5"},{"key":"2025120902351235000_13.12.e013766.22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s43018-025-00922-5","article-title":"Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial","volume":"6","author":"Bilen","year":"2025","journal-title":"Nat Cancer"},{"key":"2025120902351235000_13.12.e013766.23","doi-asserted-by":"crossref","unstructured":"Wang Y , Li Z , Deng J , et al . Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects. Adv Sci 2024;11.","DOI":"10.3389\/fimmu.2024.1485546"},{"key":"2025120902351235000_13.12.e013766.24","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200839035"},{"key":"2025120902351235000_13.12.e013766.25","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2025120902351235000_13.12.e013766.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.01.024"},{"key":"2025120902351235000_13.12.e013766.27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","article-title":"Cross-priming in cancer immunology and immunotherapy","volume":"25","author":"Luri-Rey","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"2025120902351235000_13.12.e013766.28","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-22-1046","article-title":"Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy","volume":"82","author":"Teijeira","year":"2022","journal-title":"Cancer Res"},{"key":"2025120902351235000_13.12.e013766.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.06.008"},{"key":"2025120902351235000_13.12.e013766.30","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12762","article-title":"The history of the two-signal model of lymphocyte activation: A personal perspective","volume":"89","author":"Bretscher","year":"2019","journal-title":"Scand J Immunol"},{"key":"2025120902351235000_13.12.e013766.31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1109"},{"key":"2025120902351235000_13.12.e013766.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2025120902351235000_13.12.e013766.33","doi-asserted-by":"crossref","unstructured":"Blank CU , Lucas MW , Scolyer RA , et al . Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: the phase 3 NADINA trial. N Engl J Med 2024.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA2"},{"key":"2025120902351235000_13.12.e013766.34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3390\/cancers13071525","article-title":"The Flt3L\/Flt3 Axis in Dendritic Cell Biology and CancerImmunotherapy","volume":"13","author":"Cuerto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025120902351235000_13.12.e013766.35","doi-asserted-by":"publisher","DOI":"10.1038\/S41577-019-0210-Z"},{"key":"2025120902351235000_13.12.e013766.36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4049\/jimmunol.2300038","article-title":"TLR9 plus STINGAgonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity andImproves Immune Checkpoint Blockade Efficacy in a Tumor Model","volume":"212","author":"Castro","year":"2024","journal-title":"J Immunol"},{"key":"2025120902351235000_13.12.e013766.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.10.007"},{"key":"2025120902351235000_13.12.e013766.38","doi-asserted-by":"crossref","unstructured":"Tarhini AA , Lee SJ , Davar D , et al . A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194. JCO 2025;43. doi:10.1200\/JCO.2025.43.17_suppl.LBA9505","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA9505"},{"key":"2025120902351235000_13.12.e013766.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:15:47Z","timestamp":1765278947000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,9]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/jitc-2025-013766"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013766","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}